The Vanguard Group, Inc. has recently announced that it has increased stake in Bionano Genomics Inc (NASDAQ:BNGO) by 2.91%. After grabbing 1.48 million shares, the institutional investor is now in possession of 41931.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.82% having worth around $2.36 million. Moreover, GMT Capital Corp. increased its share by 0.53 million to have a control over 0.53 million shares. And Geode Capital Management LLC raised its holdings to 43099.0 shares by acquiring 0.34 million shares or 0.88% of the stake.
Bionano Genomics Inc (BNGO) concluded trading on 12/27/23 at a closing price of $2.10, with 4.34 million shares of worth about $9.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -63.82% during that period and on Wednesday the price saw a gain of about 6.60%. Currently the company’s common shares owned by public are about 38.84M shares, out of which, 38.16M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the BNGO stock and their offered price forecasts bring an average price target of $12.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $24.00 and could fall to a lowest price of $6.00. The stock’s current price level is 82.97% above of average price target set by the analysts, while a rise to estimated low would result in gain of 65.0% for the stock. However, touching the estimated high of $24.00 would mean a gain of 91.25% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 9 times over the past 12 months. They bought 775,789 shares in 7 of the transactions. In 2 selling transactions, insiders dumped 91,637 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and SPDR S&P Kensho New Economies Com are the top 3 mutual funds which are holding stakes in Bionano Genomics Inc Vanguard Total Stock Market ETF is currently holding 0.89 million shares of worth totaling $1.41 million. The company recently came buying 0.0 shares which brought its stake up to 2.29% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 25500.0 shares, after which its hold over company’s outstanding shares expand to 1.22%, leaving 0.47 million shares with the mutual fund that have a worth of about $0.75 million. SPDR S&P Kensho New Economies Com, after buying 0.26 million shares, have now control over 0.67% of the stake in the company. It holds 0.0 shares of worth $0.41 million.
Bionano Genomics Inc (NASDAQ: BNGO) started trading at $2.10, above $0.13 from concluding price of the previous day. However, the stock later moved at a day high price of 2.1401, or with a gain of 6.60%. Stock saw a price change of 29.63% in past 5 days and over the past one month there was a price change of 37.25%. Year-to-date (YTD), BNGO shares are showing a performance of -85.62% which decreased to -86.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.19 but also hit the highest price of $20.20 during that period. The average intraday trading volume for Bionano Genomics Inc shares is 1.21 million. The stock is currently trading 31.37% above its 20-day simple moving average (SMA20), while that difference is up 36.91% for SMA50 and it goes to -58.58% lower than SMA200.
The Vanguard Group, Inc. acquired 1.48 million shares of Bionano Genomics Inc having value of about $2.36 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 41931.0 shares in the company valued at close to $88055.1, or have control over 2.91% stake in the company. Bionano Genomics Inc (NASDAQ: BNGO) currently have 38.84M outstanding shares and institutions hold larger chunk of about 13.61% of that. Holding of mutual funds in the company is about 6.55% while other institutional holders and individual stake holders have control over 7.06% and 1.19% of the stake respectively.
The stock has a current market capitalization of $81.56M and its 3Y-monthly beta is at 2.23. It has posted earnings per share of -$6.98 in the same period. It has Quick Ratio of 1.94 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BNGO, volatility over the week remained 10.20% while standing at 10.19% over the month.
Analysts are in expectations that Bionano Genomics Inc (BNGO) stock would likely to be making an EPS of -$0.87 in the current quarter, while forecast for next quarter EPS is -$0.75 and it is -$2.46 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.01 which is -$0.75 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.3 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -26.96% while it is estimated to increase by 48.88% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Bionano Genomics Inc (BNGO)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.40. Out of those 5 Wall Street analysts, 4 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on January 05, 2023 offering a Sector outperform rating for the stock and assigned a target price of $4 to it.
